益生菌对炎症性肠病诱导和维持缓解疗效的meta分析

被引：17

作者：

王霄腾

戴金锋

吕宾

机构：

[1] 浙江中医药大学附属第一医院消化内科

来源：

胃肠病学 | 2015年 / 20卷 / 01期

关键词：

炎症性肠病; 有益菌种; 随机对照试验; Meta分析;

D O I：

暂无

中图分类号：

R574 [肠疾病];

学科分类号：

100201 [内科学];

摘要：

背景:近年来益生菌广泛应用于炎症性肠病(IBD)的治疗,但其诱导和维持缓解的疗效仍存在争议。目的:系统评价益生菌对IBD诱导和维持缓解的疗效。方法:计算机检索Pub Med、CENTRAL、Embase、Web of Science、CNKI、CBM和万方数据库,收集益生菌用于IBD诱导和(或)维持缓解的随机对照试验(RCTs)。由2名研究者独立提取文献资料并交叉核对,以Cochrane偏倚风险评估工具和Jadad评分评价文献质量。应用Rev Man 5.20软件进行meta分析。结果:共纳入22项RCTs,包括溃疡性结肠炎(UC)和克罗恩病(CD)患者1 870例。Meta分析显示:1UC活动期诱导缓解率:益生菌疗效优于对照组(OR=2.34,95%CI:1.56～3.52,P<0.000 1);2UC缓解期临床复发率:益生菌疗效优于安慰剂(OR=0.15,95%CI:0.04～0.60,P=0.008),与美沙拉秦无明显差异(OR=1.00,95%CI:0.68～1.45,P=0.98);3CD活动期诱导缓解率:益生菌疗效与对照组无明显差异(OR=0.92,95%CI:0.32～2.64,P=0.88);4CD缓解期临床复发率:益生菌疗效与对照组无明显差异(OR=1.00,95%CI:0.65～1.55,P=0.98);5不良反应发生率:益生菌与对照组无明显差异(OR=1.06,95%CI:0.73～1.55,P=0.76)。结论:益生菌在UC诱导和维持缓解方面均有较好疗效,对CD则未显示出治疗优势。

引用

页码：29 / 35

页数：7

共 13 条

[1]

Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial [J].

Petersen, Andreas Munk ;

Mirsepasi, Hengameh ;

Halkjaer, Sofie Ingdann ;

Mortensen, Esben Munk ;

Nordgaard-Lassen, Inge ;

Krogfelt, Karen Angeliki .

JOURNAL OF CROHNS & COLITIS, 2014, 8 (11) :1498-1505

[2]

Saccharomyces boulardii Does Not Prevent Relapse of Crohn's Disease [J].

Bourreille, Arnaud ;

Cadiot, Guillaume ;

Le Dreau, Gerard ;

Laharie, David ;

Beaugerie, Laurent ;

Dupas, Jean-Louis ;

Marteau, Philippe ;

Rampal, Patrick ;

Moyse, Dominique ;

Saleh, Ashraf ;

Le Guern, Marie-Emmanuelle ;

Galmiche, Jean-Paul .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (08) :982-987

[3]

Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis [J].

Oliva, S. ;

Di Nardo, G. ;

Ferrari, F. ;

Mallardo, S. ;

Rossi, P. ;

Patrizi, G. ;

Cucchiara, S. ;

Stronati, L. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (03) :327-334

[4]

Disease phenotype and genotype are associated with shifts in intestinal‐associated microbiota in inflammatory bowel diseases.[J].Daniel N.Frank;Charles E.Robertson;Christina M.Hamm;ZegbehKpadeh;TianyiZhang;HongyanChen;WeiZhu;R. BalfourSartor;Edgar C.Boedeker;NoamHarpaz;Norman R.Pace;EllenLi.Inflamm Bowel Dis.2010, 1

[5]

Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double‐blind placebo‐controlled study in active Crohn’s disease.[J].H.Steed;G. T.Macfarlane;K. L.Blackett;B.Bahrami;N.Reynolds;S. V.Walsh;J. H.Cummings;S.Macfarlane.Alimentary Pharmacology & Therapeutics.2010, 7

[6]

A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp . lactis BB-12 for maintenance of remission in ulcerative colitis.[J].Signe Wildt;Inge Nordgaard;Ulla Hansen;Elke Brockmann;Jüri J. Rumessen.Journal of Crohn's and Colitis.2010, 2

[7]

The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis [J].